



Published in final edited form as:

*Cancer Causes Control*. 2013 January ; 24(1): 175–180. doi:10.1007/s10552-012-0103-y.

## Prospective study of effect modification by *Toll-Like Receptor 4* variation on the association between *Trichomonas vaginalis* serostatus and prostate cancer

Yen-Ching Chen<sup>1,2,3,\*</sup>, Yi-Ling Huang<sup>1,\*</sup>, Elizabeth A. Platz<sup>4</sup>, John F. Alderete<sup>5</sup>, Lu Zheng<sup>6</sup>, Jennifer R. Rider<sup>7</sup>, Peter Kraft<sup>6,7</sup>, Edward Giovannucci<sup>7,8,9</sup>, and Siobhan Sutcliffe<sup>10</sup>

<sup>1</sup>Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan

<sup>2</sup>Research Center for Gene, Environment, and Human Health, National Taiwan University, Taipei, Taiwan

<sup>3</sup>Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan

<sup>4</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>5</sup>School of Molecular Biosciences, Washington State University, Pullman, WA, USA

<sup>6</sup>Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA

<sup>7</sup>Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

<sup>8</sup>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>9</sup>Department of Nutrition, Harvard School of Public Health, Boston, MA, USA

<sup>10</sup>Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

### Abstract

**Purpose**—In previous studies, we observed a positive association between *Trichomonas vaginalis* serostatus and risk of prostate cancer, particularly aggressive cancer, which we hypothesized might be due to *T. vaginalis*-mediated intraprostatic inflammation and cell damage. To explore this hypothesis further, we investigated effect modification by *Toll-like receptor 4* (*TLR4*) variation on this association. We hypothesized that *TLR4* variation might serve a marker of the anti-trichomonad immune response because *T. vaginalis* has been shown to elicit inflammation through this receptor.

**Methods**—We previously genotyped the non-synonymous *TLR4* single nucleotide polymorphism (SNP), rs4986790, and determined *T. vaginalis* serostatus for 690 incident prostate cancer cases and 692 controls in a nested case-control study within the Health Professionals Follow-up Study.

Corresponding author: Yen-Ching Chen, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. Telephone: 886-2-3366-8019. Fax: 886-2-2351-1955. karenchen@ntu.edu.tw.

\*Contributed equally to this work.

Information contained in this manuscript was presented as an abstract at the American Association for Cancer Research Annual meeting in Washington, DC, in April, 2010.

**Results**—A non-significant suggestion of effect modification was observed by rs4986790 carrier status on the association between *T. vaginalis* serostatus and prostate cancer risk (p-interaction=0.07). While no association was observed among men homozygous wildtype for this SNP (odds ratio (OR)=1.23, 95% confidence interval (CI): 0.86–1.77), a positive association was observed among variant carriers (OR=4.16, 95% CI: 1.32–13.1).

**Conclusions**—Although not statistically significant, *TLR4* variation appeared to influence the association between *T. vaginalis* serostatus and prostate cancer risk consistent with the hypothesis that inflammation plays a role in this association. Larger studies will be necessary to explore this possible effect modification further.

## Keywords

*Toll-like receptor 4*; *T. vaginalis*; prostate cancer; SNP; aspirin

## Introduction

*Trichomonas vaginalis* is a common, sexually transmitted protozoan known to cause non-gonococcal urethritis, and occasionally clinical prostatitis, in a small proportion of infected men [1]. This sexually transmitted agent has been proposed as a possible cause of prostate cancer, primarily because of its ability to infect and elicit inflammation within the prostate, and because of its common occurrence [2–5]. We previously investigated possible associations between a history of *T. vaginalis* infection and prostate cancer by performing three epidemiologic studies, two of which observed a positive association between *T. vaginalis* serostatus and risk of prostate cancer, particularly high-grade [5] and advanced-stage/fatal disease [6], while the other observed no association between *T. vaginalis* serostatus and early-stage disease [7]. Collectively, these findings suggest that *T. vaginalis* may be involved in the development of aggressive prostate cancer.

Although we have not yet investigated underlying biologic mechanisms for our observed associations, some insight into these mechanisms may come from examination of variation in potentially relevant immune response genes. Recent evidence suggests that *T. vaginalis* may elicit inflammation, at least in part, through activation of the innate immune response receptor, Toll-like receptor 4 (TLR4). Cervico-lavage specimens from women infected with *T. vaginalis* were found to stimulate cytokine production by TLR4-responsive mouse splenic cells, but not TLR4-unresponsive cells [8]. Upregulated expression of *TLR4*, as well as *TLR2* and *TLR9*, was also observed in HeLa cells treated with *T. vaginalis* [9]. Therefore, we hypothesize that variation in human *TLR4* may alter signaling of the inflammatory immune response towards *T. vaginalis*, which may then, in turn, influence the risk of prostate cancer among infected men.

Some evidence exists to suggest that variant carriers of the *TLR4* SNP, rs4986790 (also known as Asp299Gly or 896A/G), which results in an amino acid change from aspartic acid to glycine, have lower levels of circulating inflammatory markers, a lesser inflammatory response to infectious stimuli, and a greater likelihood of severe infections [10]. These findings suggest that variant carriers may have a lesser ability to fight infections. In other studies, rs4986790 variant carriers have also been found to have a lower risk of cardiovascular disease [11] and allograft rejection [10], possibly further suggesting that variant carriers have a lesser degree of inflammatory immune damage or sequelae. Considering these findings in the context of *T. vaginalis* infection and prostate cancer, they might imply either a greater risk of prostate cancer for rs4986790 variant carriers because of a possibly lesser ability to clear their infection or confine it to the urethra, or they might imply a lower risk of prostate cancer because of a possibly lesser degree of inflammatory immune damage if *T. vaginalis* ascends to the prostate. To explore these hypotheses further,

we investigated effect modification by *TLR4* SNP, rs4986790, on the association between *T. vaginalis* serostatus and prostate cancer risk. To our knowledge, our study is the first such investigation.

## Methods and Materials

### Study population

In 1986, 51,529 US men ages 40 to 75 years were recruited into the Health Professionals Follow-up Study (HPFS). At baseline, participants completed a mailed questionnaire on demographics, lifestyle, and medical history, as well as a semiquantitative food frequency questionnaire. Exposure and disease information was updated every other year, and diet information was updated every four years. Blood samples were obtained from 18,018 participants between 1993 and 1995. Information on participant deaths was obtained from family members in response to follow-up questionnaires, or from the National Death Index.

All men who provided a blood sample between 1993 and 1995, and who had no report of cancer, except non-melanoma skin cancer, as of their date of blood draw were eligible for inclusion in the nested case-control study. Prostate cancer cases were defined as men with a diagnosis of prostate cancer between their date of blood draw and January 31, 2000 (n=700). For each reported case, investigators reviewed medical and pathology records or death certificates to confirm their diagnosis of adenocarcinoma of the prostate, and to obtain information on the clinical presentation, stage, and Gleason sum of their tumor. Men with incidental microscopic focal tumors (stage T1a) were not included in the analyses because these tumors are generally indolent and may be susceptible to detection bias caused by differential rates of surgery for benign prostatic hyperplasia. Cases were categorized as organ-confined/minimal extraprostatic extension (T1b-T3a and NOM0) or regionally invasive/metastatic (stage T3b, N1, or M1), and as low (Gleason sum <7) or high (Gleason sum ≥ 7) grade.

Controls (n=700) were selected from among men who were alive and free of reported prostate and other cancers, except non-melanoma skin cancer, as of the date of the case diagnosis. To allow for detection of occult prostate cancer, controls were also required to have had a prostate-specific antigen (PSA) test after their date of blood draw, typically within 2.5 years of the date of diagnosis of their matched case. Cases and controls were matched on year of birth, PSA testing before blood draw (yes/no), and time, season, and exact year of blood draw.

### Laboratory assays

Additional details of laboratory methods used for *TLR4* genotyping [12] and assessment of *T. vaginalis* serostatus [5] are described in prior publications. Briefly, we selected *TLR4* SNP, rs4986790, as a candidate SNP for genotyping because it is non-synonymous. This relatively uncommon SNP (~4% in Caucasian populations) results in an amino acid change from aspartic acid to glycine. We also selected 20 common *TLR4* SNPs with minor allele frequencies >5% in Caucasians listed in the Innate Immunity in Heart, Lung, and Blood Disease-Programs for Genomic Application database ([http://www.pharmgat.org/IIPGA2/index\\_html](http://www.pharmgat.org/IIPGA2/index_html)). The methods and results for these SNPs, which are now considered to be tag SNPs, are described in the supplemental materials. We analyzed matched case-control pairs together using the Sequenom system and genotyped SNPs in three plexes at the Harvard Partners Center for Genetics and Genomics (Boston, MA). Genotyping data were missing in <5% of study participants.

*T. vaginalis* serostatus was assessed by an enzyme-linked immunosorbent assay in the laboratory of Dr. Alderete. This assay detects IgG antibodies against purified, recombinant *T. vaginalis* -actinin protein. Seropositivity was defined as an absorbance value  $\geq 0.4$  [5].

### Statistical analysis

We investigated effect modification by *TLR4* variation on the association between *T. vaginalis* serostatus and prostate cancer risk by stratifying the analyses by rs4986790 carrier status (homozygous wildtype versus variant carrier). Stratum-specific odds ratios (ORs) were calculated by logistic regression adjusting for the matching factor, age. We determined the statistical significance of differences in the stratum-specific ORs by comparing a model with main effect terms and an interaction term to a model including only main effect terms using the likelihood ratio test.

In our previous study of *T. vaginalis* serostatus and prostate cancer risk in this cohort [5], we observed a slightly stronger positive association for high- than low-grade prostate cancer. Therefore, in the present analysis, we performed additional separate analyses by Gleason sum ( $<7$ ,  $\geq 7$ ). Too few men were diagnosed with advanced stage disease to perform separate analyses by stage. Also, in our previous study in this cohort [5], we observed stronger, positive associations between *T. vaginalis* serostatus and prostate cancer risk among infrequent and moderate lifetime aspirin users than among regular users, who we hypothesized might have had an attenuated intraprostatic inflammatory response to infection. Therefore, we also evaluated the possible interaction between *TLR4* genotype and *T. vaginalis* serostatus on prostate cancer risk among infrequent/moderate lifetime aspirin users. We defined lifetime reported aspirin use as the percentage of time that aspirin was used with any frequency from age 20 to blood draw, and we defined infrequent users as those who had used aspirin 0–19% of their lifetime and moderate users as those who had used aspirin 20–79% of their lifetime.

Analyses were conducted using SAS release 9.1 (SAS Institute, Cary, NC). Statistical tests were two sided.

### Results

Of the 700 prostate cancer cases and 700 matched controls included in our prior study of *TLR4* variation [12], 690 cases and 692 controls also had information on *T. vaginalis* serostatus (Table 1). In general, cases were similar to controls by most factors examined except for a family history of prostate cancer; cases were more likely to have a family history than controls. Among cases, the mean PSA concentration at diagnosis was 11.6 ng/mL, 72% had stage T1b to T3a disease, and 34% had a Gleason sum  $\geq 7$ .

Considering effect modification by *TLR4* variation, a non-significant suggestion of effect modification was observed by rs4986790 carrier status on the association between *T. vaginalis* serostatus and prostate cancer risk ( $p=0.07$ ). While no association was observed among men homozygous wildtype for this SNP (OR=1.23, 95% CI: 0.86–1.77), a positive association was observed among variant carriers (OR=4.16, 95% CI: 1.32–13.1). Similar patterns of association were observed for high- and low-grade prostate cancer. When the analyses were restricted to infrequent/moderate aspirin users, a slightly stronger, albeit less stable, association was observed among variant carriers and a null association was observed among wildtype homozygotes (Table 2).

## Discussion

In this large nested case-control study of US male health professionals, we observed a non-statistically significant suggestion of effect modification by *TLR4* variation on the association between *T. vaginalis* serostatus and prostate cancer risk. Specifically, we found that *T. vaginalis* serostatus was positively associated with prostate cancer risk among variant carriers of the non-synonymous *TLR4* SNP, rs4986790, but not among wildtype homozygotes.

As some evidence exists to suggest that rs4986790 variant carriers mount a weaker immune response to infectious stimuli and have more severe infections than wildtype homozygotes [10], one possible interpretation of our findings is that variant carriers may mount a less effective innate immune response against *T. vaginalis* than wildtype homozygotes and thus may be more likely to develop persistent *T. vaginalis* infections that ultimately ascend to the prostate. Low-grade anti-*T. vaginalis* intraprostatic inflammation or prostatic *T. vaginalis* infections themselves may then raise carriers' risk of prostate cancer, resulting in a positive association between *T. vaginalis* serostatus and prostate cancer risk. In contrast, men homozygous wildtype for SNP rs4986790 may mount a more effective immune response against *T. vaginalis* than variant carriers, and thus may be more likely to clear their infection and prevent it from ascending to the prostate. This hypothesized lesser likelihood of prostate infection may then reduce their risk of *T. vaginalis*-mediated prostate cancer, leading to a null association between *T. vaginalis* serostatus and risk among homozygotes. This interpretation is, however, speculative because studies have not consistently observed a weaker immune response in rs4986790 variant carriers [10].

As an additional consideration for interpreting study findings, our analysis relied on two surrogate markers (i.e., *T. vaginalis* serostatus and *TLR4* variation) to capture a number of different factors, including the likelihood of *T. vaginalis* prostatic involvement, *T. vaginalis*-mediated cell damage or other mechanisms related to carcinogenesis, and anti-trichomonad inflammation-mediated cell damage. In future studies, it would also be useful to know additional characteristics about both participants' *T. vaginalis* infection history and their anti-*T. vaginalis* immune response. For instance, with respect to *T. vaginalis* infection history, it might also be important to know whether or not the infecting isolate was itself infected with double-stranded RNA (dsRNA) viruses and/or small-sized satellite dsRNAs [13, 14]; the iron status of trichomonads at the site of infection [15–18]; the availability of host spermine for trichomonad polyamine metabolism [19]; trichomonad production of immunoglobulin-degrading cysteine proteinases [18, 20]; and trichomonad ability to colonize the basement membrane [21], all of which have been hypothesized to contribute to *T. vaginalis* persistence and thus to possible prostate involvement, or to *T. vaginalis* virulence. However, no methods currently exist, to our knowledge, to investigate these aspects of *T. vaginalis* infection history in large population-based studies.

With respect to *TLR4* genotype as a surrogate of the anti-trichomonad immune response, although *T. vaginalis* has been shown to stimulate inflammatory cytokine production through TLR4 [8], other immune receptors are also undoubtedly involved, as well as other possible mechanisms of *T. vaginalis*-mediated inflammation, such as tissue irritation by cysteine proteinases [22]. The specific immunogens or byproducts of trichomonad infection that interact with TLR4 or increase its expression are also largely unknown. For instance, although the prominent trichomonad adhesin, AP65, an anchorless surface-associated protein, is known to signal upregulated expression of numerous inflammation-associated host epithelial cell proteins, such as interleukin 8 and cyclooxygenase-2 [23], whether this interaction involves TLR4 has not been investigated. Surface expression or secretion of TLR4-binding trichomonad immunogens or byproducts may also possibly vary according to

parasite and host factors (e.g., iron status), as well as in response to host cell contact [24]. Nevertheless, despite the complexity of the host-parasite interrelation and the use of surrogate markers to capture this complexity, interesting, suggestive effect modification was observed in the present analysis supportive of a role for inflammation in the association between *T. vaginalis* infection and prostate carcinogenesis.

As a final consideration, in our previous analysis of *TLR4* variation and prostate cancer risk in the HPFS, we observed no association between rs4986790 carrier status and prostate cancer risk, consistent with other studies of *TLR4* variation and PCa [25–30]. However, this lack of association does not preclude effect modification by rs4986790 carrier status because *T. vaginalis* seroprevalence is relatively low; therefore, it is unlikely that interactions between *TLR4* genotype and *T. vaginalis* serostatus would influence marginal genetic associations to a notable degree. Moreover, it is also possible that other infections or factors might interact with *TLR4* genotype to influence prostate cancer risk; therefore, marginal genetic associations might reflect interactions with several possible factors, including *T. vaginalis* infection.

In summary, while many studies will be necessary to unravel the possible biologic mechanisms underlying observed positive associations between *T. vaginalis* serostatus and prostate cancer risk [5, 6], our novel study of the influence of *TLR4* genotype on the association between *T. vaginalis* serostatus and prostate cancer risk suggests that inflammation may play a role.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Funding for this study was provided by grants from the US National Cancer Institute (U01 CA98233 and CA55075). Siobhan Sutcliffe was funded by the Barnes-Jewish Hospital Foundation.

## References

1. Holmes, KK.; Sparling, PF.; Stamm, WE., et al., editors. Sexually transmitted diseases. 4. McGraw-Hill Medical; New York: 2008.
2. Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of cancer of the prostate. *Cancer*. 1971; 28(2):344–60. [PubMed: 5109447]
3. Gardner WA Jr, Culberson DE, Bennett BD. *Trichomonas vaginalis* in the prostate gland. *Arch Pathol Lab Med*. 1986; 110(5):430–2. [PubMed: 2421689]
4. Smith, CJ.; Gardner, WA, Jr. Inflammation-proliferation: possible relationships in the prostate. In: Coffey, DS.; Gardner, WA., Jr; NB; Resnick, MI.; Karr, JP., editors. Current concepts and approaches to the study of prostate cancer. Alan R. Liss, Inc; New York: 1987. p. 317-25.
5. Sutcliffe S, Giovannucci E, Alderete JF, et al. Plasma antibodies against *Trichomonas vaginalis* and subsequent risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2006; 15(5):939–45. [PubMed: 16702374]
6. Stark JR, Judson G, Alderete JF, et al. Prospective study of *Trichomonas vaginalis* infection and prostate cancer incidence and mortality: Physicians' Health Study. *J Natl Cancer Inst*. 2009; 101(20):1406–11. [PubMed: 19741211]
7. Sutcliffe S, Alderete JF, Till C, et al. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. *Int J Cancer*. 2009; 124(9):2082–7. [PubMed: 19117055]
8. Zariffard MR, Harwani S, Novak RM, et al. *Trichomonas vaginalis* infection activates cells through toll-like receptor 4. *Clin Immunol*. 2004; 111(1):103–7. [PubMed: 15093558]

9. Chang JH, Kim SK, Choi IH, et al. Apoptosis of macrophages induced by *Trichomonas vaginalis* through the phosphorylation of p38 mitogen-activated protein kinase that locates at downstream of mitochondria-dependent caspase activation. *Int J Biochem Cell Biol.* 2006; 38(4):638–47. [PubMed: 16360334]
10. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. *Lancet Infect Dis.* 2005; 5(3):156–64. [PubMed: 15766650]
11. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. *Atherosclerosis.* 2010; 209(2):314–20. [PubMed: 19900676]
12. Chen YC, Giovannucci E, Lazarus R, et al. Sequence variants of *Toll-like receptor 4* and susceptibility to prostate cancer. *Cancer Res.* 2005; 65(24):11771–8. [PubMed: 16357190]
13. Wang A, Wang CC, Alderete JF. *Trichomonas vaginalis* phenotypic variation occurs only among trichomonads infected with the double-stranded RNA virus. *J Exp Med.* 1987; 166(1):142–50. [PubMed: 3298522]
14. Khoshnan A, Alderete JF. Characterization of double-stranded RNA satellites associated with the *Trichomonas vaginalis* virus. *J Virol.* 1995; 69(11):6892–7. [PubMed: 7474105]
15. Lehker MW, Alderete JF. Iron regulates growth of *Trichomonas vaginalis* and the expression of immunogenic trichomonad proteins. *Mol Microbiol.* 1992; 6(1):123–32. [PubMed: 1310792]
16. Alderete JF. Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected *Trichomonas vaginalis*. *Infect Immun.* 1999; 67(8):4298–302. [PubMed: 10417210]
17. Lehker MW, Arroyo R, Alderete JF. The regulation by iron of the synthesis of adhesins and cytoadherence levels in the protozoan *Trichomonas vaginalis*. *J Exp Med.* 1991; 174(2):311–8. [PubMed: 1856625]
18. Alderete JF, Provenzano D, Lehker MW. Iron mediates *Trichomonas vaginalis* resistance to complement lysis. *Microb Pathog.* 1995; 19(2):93–103. [PubMed: 8577239]
19. Garcia AF, Benchimol M, Alderete JF. *Trichomonas vaginalis* polyamine metabolism is linked to host cell adherence and cytotoxicity. *Infect Immun.* 2005; 73(5):2602–10. [PubMed: 15845462]
20. Provenzano D, Alderete JF. Analysis of human immunoglobulin-degrading cysteine proteinases of *Trichomonas vaginalis*. *Infect Immun.* 1995; 63(9):3388–95. [PubMed: 7642267]
21. Lama A, Kucknoor A, Mundodi V, Alderete JF. Glyceraldehyde-3-phosphate dehydrogenase is a surface-associated, fibronectin-binding protein of *Trichomonas vaginalis*. *Infect Immun.* 2009; 77(7):2703–11. [PubMed: 19380472]
22. Alderete JF, Newton E, Dennis C, Neale KA. The vagina of women infected with *Trichomonas vaginalis* has numerous proteinases and antibody to trichomonad proteinases. *Genitourin Med.* 1991; 67(6):469–74. [PubMed: 1774051]
23. Kucknoor AS, Mundodi V, Alderete JF. The proteins secreted by *Trichomonas vaginalis* and vaginal epithelial cell response to secreted and episomally expressed AP65. *Cell Microbiol.* 2007; 9(11):2586–97. [PubMed: 17590165]
24. Kucknoor AS, Mundodi V, Alderete JF. Adherence to human vaginal epithelial cells signals for increased expression of *Trichomonas vaginalis* genes. *Infect Immun.* 2005; 73(10):6472–8. [PubMed: 16177319]
25. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of *toll-like receptor 4* are associated with prostate cancer risk: results from the CAnCer Prostate in Sweden Study. *Cancer Res.* 2004; 64(8):2918–22. [PubMed: 15087412]
26. Cheng I, Plummer SJ, Casey G, Witte JS. *Toll-like receptor 4* genetic variation and advanced prostate cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2007; 16(2):352–5. [PubMed: 17301271]
27. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. *Prostate.* 2009; 69(8):874–85. [PubMed: 19267370]
28. Stark JR, Wiklund F, Gronberg H, et al. Toll-like receptor signaling pathway variants and prostate cancer mortality. *Cancer Epidemiol Biomarkers Prev.* 2009; 18(6):1859–63. [PubMed: 19505919]
29. Lindstrom S, Hunter DJ, Gronberg H, et al. Sequence variants in the *TLR4* and *TLR6-1-10* genes and prostate cancer risk. Results based on pooled analysis from three independent studies. *Cancer Epidemiol Biomarkers Prev.* 2010; 19(3):873–6. [PubMed: 20200442]

30. Shui IM, Stark JR, Penney KL, et al. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. *Prostate*. 2011



**Table 1**

Baseline characteristics of prostate cancer cases and controls, Health Professionals Follow-Up Study, 1993

	Cases (n=690)	Controls (n=692)
Age at blood draw (years, mean $\pm$ SD) <sup>a</sup>	65.7 $\pm$ 7.4	65.7 $\pm$ 7.4
Family history of prostate cancer (%)	20	14
Body mass index (kg/m <sup>2</sup> , %)		
<25	62	60
25–29	33	33
30	5	7
Cigarette smoking status (%)		
Never smoker	44	44
Former smoker	46	48
Current smoker	6	5
Missing	4	3
Alcohol intake (g/day, mean $\pm$ SD)	11.4 $\pm$ 14.9	10.3 $\pm$ 14.7
Prostate specific antigen concentration (ng/mL, mean $\pm$ SD) <sup>b</sup>	11.6 $\pm$ 21	Not applicable
Stage (%) <sup>b</sup>		
T1b-T3a	72	
T3b, T4, N1, M1 or prostate cancer death	14	Not applicable
Missing	14	
Gleason sum (%) <sup>b</sup>		
<7	58	
7	34	Not applicable
Missing	8	

SD = standard deviation

<sup>a</sup> matching factor<sup>b</sup> n=501

Stratified analyses of the association between *Trichomonas vaginalis* serostatus and prostate cancer risk by *Toll-like receptor 4 (TLR4)* SNP rs4986790 carrier status, Health Professionals Follow-up Study, 1993–2000.

Table 2

	<i>T. vaginalis</i> serostatus					$P_{\text{interaction}}$
	Seronegative		Seropositive			
	Case/control	OR (ref)	Case/control	OR (95% CI)		
<b>Total prostate cancer</b>						
Homozygous wildtype (A)	507/539	1.0	71/61	1.23 (0.86–1.77)		0.07
Variant carrier (G)	96/88	1.0	16/4	4.16 (1.32–13.1)		
<b>Low-grade prostate cancer (Gleason sum&lt;7)</b>						
Homozygous wildtype (A)	272/531	1.0	38/59	1.26(0.82–1.94)		0.13
Variant carrier (G)	60/86	1.0	9/4	3.23(0.95–10.96)		
<b>High-grade prostate cancer (Gleason sum <math>\geq</math> 7)</b>						
Homozygous wildtype (A)	184/531	1.00	28/59	1.37(0.85–2.21)		0.15
Variant carrier (G)	27/86	1.00	5/4	3.98(1.00–15.9)		
<b>Only among infrequent/moderate lifetime aspirin users</b>						
Homozygous wildtype (A)	311/328	1.00	48/37	1.36 (0.86–2.15)		0.05
Variant carrier (G)	58/52	1.00	13/2	6.63 (1.39–31.7)		

CI=confidence interval; OR=odds ratio; SNP=single nucleotide polymorphism.